Kennedy Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Kennedy Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.36M	Sell	436,732 -106,116	-20%	-$1.5M	0.2%	180
2025 Q4	$5.06M	Buy	542,848 +2,464	+0.5%	+$20.6K	0.11%	293
2025 Q3	$3.81M	Buy	540,384 +86,864	+19%	+$598K	0.08%	338
2025 Q2	$2.95M	Buy	453,520 +125,829	+38%	+$866K	0.07%	376
2025 Q1	$2.6M	Buy	327,691 +133,779	+69%	+$1.44M	0.06%	400
2024 Q4	$2.46M	Buy	193,912 +4,615	+2%	+$64.2K	0.05%	483
2024 Q3	$2.64M	Buy	189,297 +15,559	+9%	+$222K	0.06%	462
2024 Q2	$2.39M	Buy	+173,738	New	+$2.54M	0.05%	482

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Kennedy Capital Management's DAWN Position: Q1 2026 in Review

Kennedy Capital Management reduced its Day One Biopharmaceuticals (DAWN) stake by 20% in Q1 2026, selling an estimated $1.5M and leaving 436,732 shares worth $9.36M. The position accounts for 0.2% of the portfolio, ranked #180.

Kennedy Capital Management first reported a position in DAWN in Q2 2024 and has held it in 8 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Kennedy Capital Management held 436,732 shares of Day One Biopharmaceuticals worth $9.36M as of Q1 2026.
Kennedy Capital Management sold 106,116 Day One Biopharmaceuticals shares in Q1 2026, an estimated $1.5M.
Day One Biopharmaceuticals made up 0.2% of Kennedy Capital Management's portfolio in Q1 2026, its #180 holding.
Kennedy Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2024 and has held it in 8 quarters since.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.